Skip to main content
Premium Trial:

Request an Annual Quote

GIS, Sengenics Partner on Biomarkers for Early Detection of Cancer

NEW YORK (GenomeWeb News) – The Genome Institute of Singapore and Sengenics said today that they have formed a partnership to identify and validate auto-antibody signatures for the early detection of cancers.

The collaboration will use protein microarray technology from Senegenics' strategic partner, Oxford Gene Technology, and will focus initially on gastric and breast cancers.

As part of the partnership, Sengenics will establish its research biomarker discovery facility at GIS this year. The goal, noted GIS Executive Director Ng Huck Hui in a statement, is to combine the antibody biomarkers discovered via the collaboration with GIS's existing proprietary genomic data to "potentially develop a new range of powerful oncology prognostic tests specific to the Singaporean population."

According to Sengenics Commercial Director Johan Poole-Johnson, the partners anticipate completing the first phase of the project within 12 months.

Financial and other terms of the agreement were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.